MCRB (Seres Therapeutics) FCF Margin %: -3,042.66% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MCRB Seres Therapeutics Inc MCRB
13 GF Score
Price $4.76
! 5 Warning Signs
View Full Analysis

What is Seres Therapeutics FCF Margin %?

Seres Therapeutics MCRB -4.80% 13 FCF Margin % is -3,042.66% as of Jun. 2026. GuruFocus rates MCRB with a GF Score™ of 13/100. The stock has 5 warning signs investors should review. Among 956 Biotechnology companies, Seres Therapeutics ranks worse than 86.61% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Seres Therapeutics's Free Cash Flow for the three months ended in Jun. 2026 was $-22.39 Mil. Seres Therapeutics's Revenue for the three months ended in Jun. 2026 was $0.74 Mil. Therefore, Seres Therapeutics's FCF Margin % for the quarter that ended in Jun. 2026 was -3,042.66%.

As of today, Seres Therapeutics's current FCF Yield % is -107.28%.

The historical rank and industry rank for Seres Therapeutics's FCF Margin % or its related term are showing as below:

MCRB' s FCF Margin % Range Over the Past 10 Years
Min: -2724.11   Med: -224.67   Max: 109.63
Current: -2724.11

During the past 13 years, the highest FCF Margin % of Seres Therapeutics was 109.63%. The lowest was -2724.11%. And the median was -224.67%.

MCRB's FCF Margin % is ranked worse than
86.61% of 956 companies
in the Biotechnology industry
Industry Median: -80.565 vs MCRB: -2724.11

Seres Therapeutics FCF Margin % Related Terms

Seres Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Seres Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seres Therapeutics FCF Margin % Chart

Seres Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.99 0.00 0.00 0.00 109.63

Seres Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -1,868.06 -4,569.83 -3,042.66

MCRB vs IBO, TIL, ATYR: FCF Margin % Comparison

For the Biotechnology subindustry, Seres Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Seres Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seres Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Seres Therapeutics's FCF Margin % falls into.


MCRB
13GF Score
Seres Therapeutics Inc MCRB
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seres Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Seres Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=0.865/0.789
=109.63 %

Seres Therapeutics's FCF Margin for the quarter that ended in Jun. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=-22.394/0.736
=-3,042.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -3,042.66% mean?
Seres Therapeutics (MCRB) has a FCF Margin % of -3,042.66% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Seres Therapeutics and its competitors. According to the industry distribution chart, Seres Therapeutics ranks #828 out of 956 companies in the Biotechnology industry, placing it in the top 86.6%.
Is Seres Therapeutics' FCF Margin % too high?
Seres Therapeutics' current FCF Margin % is -3,042.66%. Based on the distribution chart, Seres Therapeutics ranks #828 out of 956 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Seres Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Seres Therapeutics' FCF Margin % compare to IBO and TIL?
According to the Biotechnology industry distribution chart, Seres Therapeutics ranks #828 out of 956 companies for FCF Margin %. This places Seres Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Seres Therapeutics and its competitors. Seres Therapeutics's current FCF Margin % is -3,042.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seres Therapeutics stock overvalued right now?
Seres Therapeutics (MCRB) has a current FCF Margin % of -3,042.66%. The current FCF Margin % is -3,042.66%. Seres Therapeutics' overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Seres Therapeutics (MCRB), the current FCF Margin % is -3,042.66% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seres Therapeutics Business Description

Other Exchanges 1S90:Germany
Address 101 Cambridgepark Drive, Cambridge, MA, USA, 02140
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
13GF Score

Get the complete analysis for MCRB

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.76
Price